Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A propensity score-matched comparison of recurrence outcomes after immediate implant vs autologous flap reconstruction in patients receiving neoadjuvant chemotherapy for breast cancer.
Wu ZY, Han HH, Kim HJ, Lee JW, Chung IY, Kim J, Lee SB, Son BH, Eom JS, Jung JH, Kim SB, Gong G, Kim HH, Ahn S-, Ko B. Wu ZY, et al. Among authors: kim sb, kim hh, kim hj, kim j. Breast Cancer Res Treat. 2021 Jun;187(2):417-425. doi: 10.1007/s10549-021-06114-w. Epub 2021 Mar 19. Breast Cancer Res Treat. 2021. PMID: 33740204
An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer.
Park IH, Sohn JH, Kim SB, Lee KS, Chung JS, Lee SH, Kim TY, Jung KH, Cho EK, Kim YS, Song HS, Seo JH, Ryoo HM, Lee SA, Yoon SY, Kim CS, Kim YT, Kim SY, Jin MR, Ro J. Park IH, et al. Among authors: kim sb, kim cs, kim ty, kim sy, kim ys, kim yt. Cancer Res Treat. 2017 Jul;49(3):569-577. doi: 10.4143/crt.2016.289. Epub 2016 Sep 12. Cancer Res Treat. 2017. PMID: 27618821 Free PMC article. Clinical Trial.
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE, Lee KS, Watanabe J, Ohtani S, Kim SB, Kuroi K, Tsugawa K, Tokuda Y, Iwata H, Park YH, Yang Y, Nambu Y. Fujiwara Y, et al. Among authors: kim sb. Br J Cancer. 2019 Mar;120(5):475-480. doi: 10.1038/s41416-019-0391-z. Epub 2019 Feb 12. Br J Cancer. 2019. PMID: 30745582 Free PMC article. Clinical Trial.
Risk Factors for Postoperative Recurrence in Korean Patients with Crohn's Disease.
Kim SB, Cheon JH, Park JJ, Kim ES, Jeon SW, Jung SA, Park DI, Lee CK, Im JP, Kim YS, Kim HS, Lee J, Eun CS, Lee JM, Jang BI, Seo GS. Kim SB, et al. Among authors: kim ys, kim hs, kim es. Gut Liver. 2020 May 15;14(3):331-337. doi: 10.5009/gnl19085. Gut Liver. 2020. PMID: 31550869 Free PMC article.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. Among authors: kim sb, kim mh, kim jh. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
2,461 results